Literature DB >> 15382304

Current state of imaging for lung cancer staging.

Michael S Kent1, Jeffrey L Port, Nasser K Altorki.   

Abstract

Proper selection and interpretation of imaging studies is essential to provide optimal treatment to patients who have lung cancer. The following combines the recommendations of the American College of Chest Physicians [74] and the authors' current clinical practice guidelines: --All patients who have known or suspected lung cancer should undergo a CT of the chest and upper abdomen. --An FDG-PET study should be performed, if available. --Mediastinoscopy should be performed in all patients except those who have peripheral small (<2 cm) tumors and no evidence of N2 disease on CT or PET imaging. --MRI should be performed for tumors of the superior sulcus to define the relationship of the tumor to adjacent neurovascular structures. --Patients who have neurologic signs or symptoms should undergo a brain imaging study (CT or MRI). --Screening for extrathoracic disease is not necessary in asymptomatic patients who have clinical stage I or II disease.

Entities:  

Mesh:

Year:  2004        PMID: 15382304     DOI: 10.1016/S1547-4127(04)00031-3

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  3 in total

1.  Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.

Authors:  Helga Sertić Milić; Ana Franjević; Gordana Bubanović; Ante Marušić; Igor Nikolić; Igor Puljić
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

2.  [99Tc(m) -N(NOEt)2 uptake kinetics difference among KMB17 human embryonic lung diploid fibroblast and different human lung cancer cells].

Authors:  Tiekun Ma; Jianming Cao; Wei Jia
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-04

Review 3.  Imaging and cancer: a review.

Authors:  Leonard Fass
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 7.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.